Loading...
Loading...
FREQ| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 12.7M |
| Operating I/L | -12.7M |
| Other Income/Expense | 1.0M |
| Interest Income | 0.4M |
| Pretax | -11.6M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -11.6M |
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing therapeutics to activate the body's innate regenerative potential. Their Progenitor Cell Activation approach utilizes small molecules to stimulate progenitor cells, aiming to restore functional tissue. The company's lead product candidate, FX-322, is in Phase IIa clinical trial for treating sensorineural hearing loss. Additionally, they are developing medicines for degenerative conditions such as multiple sclerosis, muscle, gastrointestinal tract, skin, and bone diseases. Frequency Therapeutics has collaboration agreements with Astellas Pharma Inc., Massachusetts Eye and Ear, Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.
